A Randomised, Open-Label, Cross-Over Study to Examine the Pharmacokinetics and Short-Term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-Infected Patients.
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2012
At a glance
- Drugs Atazanavir (Primary) ; Raltegravir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms SPARTA
- 10 Jun 2017 Biomarkers information updated
- 11 Apr 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.